Program launch date: 19th September 2020 Accreditation expiration date: 3rd December 2021 Welcome to this independent medical education program on the optimal use of CDK4/6 inhibitors to treat HR+ HER2- advanced breast cancer. This program is designed for global oncologists and other healthcare professionals involved in the diagnosis, treatment, and follow-up of patients with breast cancer.
Click above to watch an outline of the program
Program at a glance

Watch individual presentations by our panel of international experts on the latest trial data and prescribing guidelines for CDK4/6 inhibitors, what inhibitors to use and when for different patient characteristics and how to manage adverse events associated with their use.

This article will helpfully summarize the findings from each key clinical trial of CDK 4/6 inhibitors in HR+ HER2- advanced breast cancer, as well as provide useful links to clinical trial repositories and associated information.

Javier Cortes

IOB Institute of Oncology, Madrid and Barcelona; Vall d´Hebron Institute of Oncology, Barcelona, Spain

Dr Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996. He continued his studies at the University of Navarra, specialising in Medical Oncology at the Clínica Universitaria de Navarra, where he continued as Assistant in the Department of Oncology from 2002. He was Associated Professor of Oncology in the Faculty of Medicine at the University of Navarra during that period. Dr Cortes was awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. 

From June 2003 to July 2015, he has worked in the Department of Medical Oncology at the Hospital Vall d’Hebron, Barcelona, where he has been Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in the Area of Breast Cancer with a special interest in New Drugs Development. Dr Cortes was the Head of the Breast Cancer Program and the Melanoma Unit from July 2006 to August 2015. 

From September 2015 to October 2018, he has been Head of the Breast Cancer and Gynecological tumors at Ramon y Cajal University Hospital in Madrid. Dr Cortes is the Head of the Breast Cancer Program at IOB Institute of Oncology, Quironsalud group, in both Madrid and Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials and Senior Clinical Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology.

In addition to his medical specialties, he has two masters’ degrees in “Medical Direction and Clinical Management” from the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” from the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” from the Universidad Autonoma de Barcelona.

He is the author of more than 260 publications, especially about breast tumors and new drugs and more than 500 communications at different conferences. He actively participates in the development of numerous international clinical trials, and he is an ad hoc reviewer of various oncology journals, including, New England Journal of Medicine, The LancetLancet Oncology, Annals of Oncology or Journal of Clinical Oncology, among many others.

Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO). In addition, he is a member of the Scientific Committee of the European Society of Medical Oncology (ESMO), Chair of the Committee for Breast Cancer, local therapy, ESMO 2020 and Co-Chair of the American Association for Cancer research (AACR) Annual Meeting 2021 Program Committee.


Consulting/Advisor: Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Kyowa Kyrin.; Honoraria: Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo.;  Research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London;  Stock, patents and intellectual property: MedSIR;  Travel, accommodation, expenses: Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo.

Nadia Harbeck

University of München, Germany

Nadia Harbeck, MD, PhD, is head of the Breast Centre and holds the chair for conservative oncology at the University of Munich (LMU), Germany, following a post as head of the Breast Centre at the University of Cologne from 2009 to 2011. After gaining her medical degree in 1989, she received her specialist training in obstetrics and gynaecology at the Technical University of Munich, where she then worked as an associate professor and head of conservative senology until 2009.

Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based German Gynecological Oncology Working Group guidelines for breast cancer therapy ( and co-director of the West German Study Group ( From 2009 to 2015, she served as an executive board member of the European Organisation for Research and Treatment of Cancer (EORTC) and as chair of the EORTC translational research division. She is principal investigator or steering committee member of numerous national and international clinical breast cancer trials, focusing on novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She also has a strong interest in eHealth and is a co-developer of the digital patient diary CANKADO (

In 2020, Professor Harbeck received the ESMO Lifetime Achievement Award. For her clinical translational research, she has also received the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2002 AGO Schmidt-Matthiesen Award, a 2001 American Association for Cancer Research Award, and the 2001 American Society of Clinical Oncology Fellowship Merit Award for the highest-ranking abstract submitted.

Professor Harbeck is the author of more than 480 papers in peer-reviewed journals and is coordinating editor-in-chief of Breast Care. She is a panel member of several International Consensus Conferences such as Breast Cancer in Young Women (BCY), Advanced Breast Cancer (ABC), and the St Gallen Meeting for Early Breast Cancer.


Honoraria for lectures and/or consulting: AstraZeneca, Lilly, Novartis, Pfizer; Institutional: Clinical phase II-IV trials; Other: Co-Director West German Study Group (WSG).

George W Sledge Jr.

Stanford University Medical Center, CA, USA

Dr George W Sledge Jr. is Professor of Medicine and Chief, Division of Oncology, at the Stanford University School of Medicine and co-director of the Stanford Cancer Institute’s translational oncology program.

Trained in internal medicine and medical oncology, he has devoted his professional career to understanding the biology and improving the treatment of breast cancer. He is active as both a laboratory and clinical researcher, with more than 380 scientific publications.

He served as chair of the Eastern Cooperative Oncology Group’s Breast Cancer Committee (2003-2010), as a member of the Food and Drug Administration’s Oncology Drug Advisory Committee, and as a member of the Department of Defense’s breast cancer research program’s integration panel.

Dr Sledge Jr. is past president of the American Society of Clinical Oncology, and currently serves as the chief scientific advisory boards for Susan G. Komen and as a member of the scientific advisory board for the Triple Negative Breast Cancer Foundation.

He is the recipient of numerous scientific awards, including the Breast Cancer Research Foundation’s Jill Rose Award, the Komen Foundation’s Brinker Award for Scientific Distinction, and the San Antonio Breast Cancer Symposium’s William L. McGuire Award.

His research interests have focused on novel biologic approaches to breast cancer therapy.


Scientific Advisory Board: Eli Lilly, Verseau Therapeutics; Board of Directors: Tessa Therapeutics; Research Support: Pfizer, Genentech/Roche.

Learning objectives

After participating in the program, the target audience will be able to:

  • Summarize the latest data and guidelines on the optimal use of CDK4/6 inhibitors in the treatment of HR+ HER2- advanced breast cancer
  • Compare the toxicity profiles of the different CDK4/6 inhibitors in order to make optimal treatment decisions
  • Apply evidence-based, personalized best practice in the selection, sequencing, and dosing of CDK4/6 inhibitors

In support of improving patient care, the webcast activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME), Imedex, and Springer Healthcare IME. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this on-demand activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to claim your credits

To claim your credits for participating in the accredited activities, you will need to take part in the full on-demand webcast then fill out the short evaluation form at the end of the activity and tick the appropriate box.

Disclosure of relevant financial relationships

NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

NACCME requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Planning committee

In addition to the speaker faculty, NACCME and Springer Healthcare IME planners and staff include Chris Bolwell, James Hutton and Rebecca Hills.

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service. James Hutton and Rebecca Hills have no financial relationships to disclose.


This activity is supported by an educational grant from Lilly.

Contact us


Address: Springer Healthcare IME
The Campus
4 Crinan Street
N1 9XW